Preview

Rational Pharmacotherapy in Cardiology

Advanced search

DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT

https://doi.org/10.20996/1819-6446-2017-13-1-95-99

Full Text:

Abstract

The review actualizes the need to validate data  obtained in randomized clinical trials (RCT) by the results of routine clinical practice (RCP). Definitely, both methods have some disadvantages. Only patients with minimal comorbidity and a number of other restrictions are included into the RCT in accordance with strict procedures and treatment protocol. On the contrary, the analysis of the RCP shows that data  bases  of insurance companies and medical records are associated with less exact information about the patients, heterogeneity of comparison groups might be significant, and end points evaluation can be different. At the same time, if the RCT data are confirmed by the key results of the RCP analysis, it is a strong  evidence of the credibility of information, obtained by the both methods. The analysis of various RCP data bases published over the past 2 years shows that, among all new oral anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence in patients with non-valvular atrial fibrillation. These results confirm good safety profile of apixaban which was previously demonstrated in ARISTOTLE trial. On the contrary, rivaroxaban was associated with the most frequent bleeding in long-term use in patients with atrial fibrillation.

About the Authors

D. А. Napalkov
I.M. Sechenov First Moscow State Medical University
Russian Federation

Dmitry A. Napalkov – MD, PhD, Professor, Chair of Faculty Therapy №1, Medical Faculty.

Trubetskaya ul. 8-2, Moscow, 119991



A. A. Sokolova
I.M. Sechenov First Moscow State Medical University
Russian Federation

Anastasiya A. Sokolova – MD, PhD, Assistant, Chair of Faculty Therapy №1, Medical Faculty.

Trubetskaya ul. 8-2, Moscow, 119991



V. V. Fomin
I.M. Sechenov First Moscow State Medical University
Russian Federation

Viktor V. Fomin – MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Head of Chair of Faculty Therapy №1, Medical Faculty.

Trubetskaya ul. 8-2, Moscow, 119991



References

1. Sacristan J.A. Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients. BMC Medical Informatics and Decision Making. 2013;13:6.

2. Booth C.M., Tannock I.F. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551-5.

3. Grjibovski A.M., Ivanov S.V., Gorbatova M.A., Dyusupov A.A. Using psevdorandomizatsii (propensity score matching) to eliminate systematic differences between comparison groups in observational studies with dichotomous outcomes. Ekologiia Cheloveka. 2016; 5: 50-64. (In Russ.) [Гржибовский А.М., Иванов С.В., Горбатова М.А., Дюсупов А.А. Использование псевдорандомизации (propensity score matching) для устранения систематических различий между сравниваемыми группами в обсервационных исследованиях с дихотомическим исходом. Экология Человека. 2016;5:50–64].

4. Lee S., Monz B.U., Clemens A., et al. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open. 2012;2(6):e001768.

5. Kalra L., Yu G., Perez I., et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ. 2000;320(7244): 1236-9.

6. Samsa G.P., Matchar D.B., Goldstein L.B., et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000;160(7):967-73.

7. Matchar D.B., Samsa G.P., Cohen S.J., et al. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 2002;113(1):42-51.

8. Sokolova A.A., Zhilenko A.V., Tsarev I.L., et al. Practical aspects of the use of anticoagulant therapy in patients with non-valvular atrial fibrillation the etiology: University Hospital data register. Rossiyskiy Kardiologicheskiy Zhurnal. 2015;9(125):32-7. (In Russ.) [Соколова А.А., Жиленко А.В., Царев И.Л., и др. Практические аспекты применения антикоагулянтной терапии у пациентов с фибрилляцией предсердий неклапанной этиологии: данные регистра университетской клиники. Российский Кардиологический Журнал. 2015;9(125):32-7].

9. Yao X., Abraham N.S., Alexander G.C., et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2):e003074.

10. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78.

11. Sokolova A.A., Tsarev I.L., Napalkov D.A., Sulimov V.A. Monitoring of patients with non-valvular atrial fibrillation etiology through the work of the office monitoring of anticoagulant therapy: long-term efficient and safe use of anticoagulants. Farmateka. 2016;6(319):45-50. (In Russ.) [Соколова А.А., Царев И.Л., Напалков Д.А., Сулимов В.А. Наблюдение за пациентами с фибрилляцией предсердий неклапанной этиологии в рамках работы кабинета контроля антикоагулянтной терапии: длительное эффективное и безопасное применение антикоагулянтов. Фарматека. 2016;6(319):45-50].

12. Lip G.Y.H, Keshishian A., Kamble S., et al. Real-world comparison of major bleeding risk among nonvalvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116(5):975-86.


For citation:


Napalkov D.А., Sokolova A.A., Fomin V.V. DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT. Rational Pharmacotherapy in Cardiology. 2017;13(1):95-99. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-1-95-99

Views: 603


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)